Peggy Scherle
2022
In 2022, Peggy Scherle earned a total compensation of $1.6M as Chief Scientific Officer at Prelude Therapeutics, a 38% decrease compared to previous year.
Compensation breakdown
| Bonus | $300,000 |
|---|---|
| Non-Equity Incentive Plan | $142,800 |
| Option Awards | $761,865 |
| Salary | $416,667 |
| Other | $9,150 |
| Total | $1,630,482 |
Scherle received $761.9K in option awards, accounting for 47% of the total pay in 2022.
Scherle also received $300K in bonus, $142.8K in non-equity incentive plan, $416.7K in salary and $9.2K in other compensation.
Rankings
In 2022, Peggy Scherle's compensation ranked 2,085th out of 5,753 executives tracked by ExecPay. In other words, Scherle earned more than 63.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,085 out of 5,753 | 64th |
Division Manufacturing | 1,122 out of 3,133 | 64th |
Major group Chemicals And Allied Products | 480 out of 1,419 | 66th |
Industry group Drugs | 440 out of 1,320 | 67th |
Industry Pharmaceutical Preparations | 320 out of 966 | 67th |
Source: SEC filing on April 28, 2023.
Scherle's colleagues
We found two more compensation records of executives who worked with Peggy Scherle at Prelude Therapeutics in 2022.